Canaccord initiated coverage of Celldex (CLDX) with a Buy rating and $64 price target Celldex is a late-stage clinical biotech company that is focused on drug development in the immunology and inflammation space, the analyst tells investors in a research note. The firm believes the company’s lead drug barzolvolimab is addressing two key commercial opportunities and fits well into the “pipeline-in-a-drug” category.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLDX:
- Celldex initiated with an Overweight at Morgan Stanley
- Celldex’s Barzolvolimab: Promising Phase 2 Results and Strong Buy Rating
- Celldex presents preclinical data from CDX-622 at AAAAI 2025
- Celldex’s Promising Clinical Developments and Strategic Advancements Lead to Buy Rating
- Celldex announces data from Phase 2 barzolvolimab studies